Hyperbaric oxygen therapy restores tissue oxygenation and promotes healing in peripheral artery disease
Hyperbaric oxygen therapy restores tissue oxygenation and promotes healing in peripheral artery disease
Understanding peripheral artery disease and how HBOT restores tissue oxygenation and promotes healing
Peripheral artery disease (PAD) is a common circulatory condition in which atherosclerosis — the buildup of fatty plaque in the arteries — narrows and eventually blocks the arteries supplying the legs. An estimated 8 to 10 million Americans have PAD, with risk increasing substantially with age, diabetes, smoking and cardiovascular disease.
PAD presents across a clinical spectrum. In its milder forms, it causes intermittent claudication — cramping pain, aching or weakness in the calf, thigh or buttock that occurs with walking and is relieved by rest, reflecting insufficient oxygen delivery to exercising leg muscles. In its most severe form — critical limb ischemia (CLI) — PAD causes rest pain, non-healing ulcers and tissue death (gangrene) that threatens limb viability and requires urgent intervention to prevent amputation.
Non-healing leg and foot wounds in PAD patients are particularly challenging. These wounds fail because the tissue oxygen tensions in ischemic limbs are too low to support the cellular processes needed for wound healing: fibroblast activity, collagen deposition, immune cell function and angiogenesis. HBOT directly addresses this by delivering concentrated oxygen to hypoxic wound tissue, restoring the metabolic environment for healing. HBOT also triggers therapeutic angiogenesis — the growth of new collateral blood vessels — that over a treatment course progressively improves perfusion to ischemic tissue beyond what the arterial blockages allow.
For PAD patients with non-healing wounds meeting Medicare criteria, HBOT may be covered as part of an approved wound care program. We work with your vascular and wound care teams to determine whether your specific wound qualifies and to coordinate prior authorization.
Claudication — cramping, aching or leg fatigue with walking, relieved by rest
Non-healing wounds, ulcers or sores on the lower leg or foot
Rest pain — severe leg or foot pain even at rest, indicating critical ischemia
Cold, pale or bluish skin on the affected limb
Slow-growing or brittle toenails and leg hair loss from chronic ischemia
Gangrene and limb loss in untreated critical limb ischemia
How HBOT supports tissue survival and healing in peripheral artery disease
PAD creates a cascade of ischemia, hypoxia, inflammation and failed healing. HBOT addresses each element of this cascade simultaneously, making it one of the few interventions with a broad therapeutic impact in PAD.
Stimulates new blood vessel growth in ischemic leg tissue
Restores oxygen delivery to hypoxic wound tissue
Reduces limb inflammation and pain
Reduces infection risk in ischemic wounds
Improves walking distance in claudication
Supports limb salvage and reduces amputation risk
For Providers
Clinical evidence for HBOT in peripheral artery disease
HBOT for PAD and critical limb ischemia is supported by controlled studies and meta-analyses demonstrating improvements in wound healing, limb salvage rates and walking performance.
Hammarlund and Sundberg — RCT in chronic leg ulcers (1994): A landmark randomized, double-blind, placebo-controlled trial published in Plastic and Reconstructive Surgery demonstrated that HBOT significantly improved healing in chronic leg ulcers compared to sham treatment. At 6 weeks, the HBOT group showed 35% greater wound area reduction and higher rates of complete healing, establishing the evidence base for HBOT in vascular wound failure. [Hammarlund C, Sundberg T. Plast Reconstr Surg. 1994;93(4):829–834. PMID: 8134481]
Fife et al. — retrospective analysis (2007): A large retrospective analysis of 1,144 patients in the Wound Registry database demonstrated that patients with non-healing wounds associated with PAD and diabetes treated with HBOT had significantly higher rates of wound healing and limb salvage compared to similar patients not receiving HBOT. Patients with transcutaneous oxygen measurements above 200 mmHg during HBOT showed the best outcomes. [Fife CE et al. Wound Repair Regen. 2007;15(6):847–855. PMID: 18028134]
Angiogenesis mechanism: HBOT's angiogenic effects in ischemic tissue are among its most important mechanisms in PAD. HBOT upregulates hypoxia-inducible factor (HIF-1α) and VEGF in ischemic muscle, stimulating the growth of collateral blood vessels that provide alternative perfusion pathways around arterial blockages. This process, documented in animal models and human biopsy studies, creates a lasting improvement in tissue perfusion that persists beyond the treatment course. [Thom SR et al. Am J Physiol. 2011;300(1):H294–305. PMID: 21057048]
Transcutaneous oxygen monitoring: The tissue oxygen tension achieved during HBOT — measured by transcutaneous oximetry (TcPO2) — is the most reliable predictor of treatment response in PAD wounds. Patients achieving TcPO2 above 200 mmHg during HBOT consistently show better healing outcomes. We use TcPO2 monitoring to confirm treatment adequacy and identify patients most likely to benefit.
Our PAD HBOT protocol at Bay Area Hyperbarics
HBOT is most effective in PAD when used alongside appropriate vascular interventions — not as a replacement for revascularization where feasible. We coordinate with your vascular team to deliver HBOT as a synergistic component of your comprehensive PAD management plan.
Vascular assessment and care team coordination
Our medical team reviews your PAD severity, ankle-brachial index, current vascular interventions and wound status. We coordinate with your vascular surgeon or cardiologist to ensure HBOT is integrated as a complementary element of your overall PAD management plan, alongside revascularization, wound care and cardiovascular risk management.
HBOT sessions to restore tissue oxygenation and stimulate angiogenesis
You breathe 100% oxygen at 2.0 to 2.4 atmospheres absolute for approximately 90 minutes per session. PAD protocols typically involve 30 to 40 sessions, with non-healing wound cases sometimes requiring 40 or more sessions. Sessions are scheduled once daily, five days per week.
Wound monitoring and limb viability assessment
We track wound healing progress, ankle-brachial index trends, pain-free walking distance and overall limb viability throughout treatment. We work closely with your wound care and vascular teams, providing HBOT-session-specific data to support coordinated limb salvage planning.
Frequently Asked Questions
Answers to the questions PAD patients most often ask about hyperbaric oxygen therapy.
Revascularization — bypass surgery or angioplasty — treats the arterial blockage itself and is the primary intervention for severe PAD where feasible. HBOT treats the tissue consequences of ischemia: hypoxic wound failure, inflammation and impaired healing. In patients where revascularization is not possible, HBOT can provide an alternative pathway for tissue oxygenation through dissolved plasma oxygen and angiogenesis. In patients who have undergone revascularization, HBOT can improve healing in wounds that remain hypoxic even after improved arterial flow.
Living with PAD? Ask us how HBOT can help
Bay Area Hyperbarics provides HBOT for PAD-related non-healing wounds and limb ischemia. Call us to discuss your vascular history and whether HBOT can help preserve your limb and restore your mobility.
